Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Candidate therapies with tyrosine kinase inhibitors in CP-CML patients lacking deep molecular response
2015-005208-26Phase 2Active
- Sponsor
- Centre Hospitalier de Versailles
- Start
- Apr 2016
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of imatinib, nilotinib, dasatinib, bosutinib and ponatinib in chronic myelogenous leukemia (CML), sponsored by Centre Hospitalier de Versailles. Primary endpoint: Cumulative incidence of MR4.5 or deeper by 12 months. Started Apr 2016; status: active.
02
Drugs
03
Conditions
chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on 2015-005208-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-005208-26.